key: cord-0984137-k5s6b9a1 authors: Korayem, Ghazwa B.; Aljuhani, Ohoud; Altebainawi, Ali F.; Shaya, Abdulrahman I Al; Alnajjar, Lina I.; Alissa, Abdulrahman; Aldhaeefi, Mohammed; Kensara, Raed; Muqati, Hessa Al; Alhuwahmel, Abdulmohsen; Alhuthaili, Omar; Vishwakarma, Ramesh; Aldardeer, Namareq; Eljaaly, Khalid; Alharbi, Aisha; Harbi, Shmeylan Al; Katheri, Abdulmalik Al; Bekairy, Abdulkareem M. Al; Aljedai, Ahmed; Sulaiman, Khalid Al title: The Safety and Efficacy of Tocilizumab in Older Adult Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Multi-center, Cohort Study date: 2022-05-20 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.05.038 sha: 10e1d0f13fdaedb70e1568561fbb876da642db09 doc_id: 984137 cord_uid: k5s6b9a1 Background Evidence supports Tocilizumab (TCZ) benefit and safety in adult patients with severe COVID-19. However, its effectiveness in critically ill older adult patients remains questionable. Thus, the study aimed to evaluate the safety and efficacy of TCZ in older critically ill patients with COVID-19. Method A multicenter, retrospective study for all critically ill older adults (aged ≥ 65 years old) with confirmed COVID-19 infection and admitted to the intensive care units. Eligible patients were categorized into two groups based on TCZ use during ICU stay (Control vs. TCZ). Propensity score matching was used (1:1 ratio) based on the selected criteria. The primary outcome was in-hospital mortality. Results A total of 368 older adults critically ill patients were included in the study. Fifty-one patients (13.8%) received TCZ. The in-hospital mortality was lower in the TCZ treated group HR (0.41 [95% CI 0.22-0.76], p-value =0.005). Patients who received TCZ had a lower odd of respiratory failure requiring mechanical ventilation OR (0.32 [95% CI 0.10-0.98]), p-value=0.04). No statistically significant differences were found between the two groups for 30- days mortality, ventilator-free days, length of stay, and complications during ICU stay. Conclusion TCZ use in older adults critically ill patients with COVID-19 is associated with lower in-hospital mortality and similar safety profile. • Highlights:  The hyperinflammatory stage in COVID is characterized by surges of IL-6  The role of tocilizumab (TCZ) (IL-6 inhibitor) in COVID patients is controversial  TCZ have immunosuppressive effects which can be dubious in older COVID- 19 patients  TCZ exhibited less in-hospital mortality but similar 30-d mortality in our study  No difference between groups in the incidence of secondary infections in our study Since the novel severe acute respiratory syndrome coronavirus emergence in 2019 (Huang et al., 2020) , coronavirus disease 2019 has caused more than four million deaths globally. (Organization, 2021) COVID-19 pneumonia can progress to acute respiratory distress syndrome (ARDS), multiorgan dysfunction, or death [3] . This progression may be attributed to the body's inflammatory response exacerbating inflammatory mediators such as cytokines and chemokines, leading to cytokine storm. (Que et al., 2022) Therefore, many treatment modalities such as antiviral therapy, antibiotic therapy, immunomodulating agents, and corticosteroids have been investigated to mitigate COVID-19 symptoms, reduce disease progression, and ultimately prevent mortality. (Gordon et al., 2021; Shaffer, 2020; Tocilizumab in patients admitted to hospital with COVID-19 ( COVID-19 reported a lower mortality rate in patients receiving TCZ. (Alkofide et al., 2021) Moreover, a recent systematic review and meta-analysis including 52 studies confirmed TCZ mortality benefits in the intensive care unit (ICU) and non-ICU patients regardless of the use of systemic corticosteroids, but TCZ did not significantly reduce mortality in the included observational studies. (Kyriakopoulos et al., 2021) Even though most evidence supports the efficacy of TCZ use in patients with severe COVID-19 (Van den Eynde et al., 2021; Gordon et al., 2021; Kimmig et al., 2020; Kyriakopoulos et al., 2021; Mahale et al., 2020; Each patient's data were collected and handled using King Abdullah International Medical Research Center's (KAIMRC) Research Electronic Data Capture (REDCap®) version 9.1.2 software. The following demographic and laboratory data were collected: comorbidities, vital signs. In addition to renal profile (i.e., estimated glomerular filtration rate (eGFR)), liver function tests (LFTs) (i.e., total bilirubin, ALT, AST), coagulation profile (i.e., INR, aPTT, platelets count), and inflammatory markers (ferritin, D-dimer, and C-reactive protein (CRP)) within 24 hours of ICU admission. Moreover, severity score baseline (i.e., Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA)), Glasgow Coma Score (GCS), acute kidney injury (AKI), prone positioning, the needs for mechanical ventilation (MV) and MV parameters (e.g., PaO2/FiO2 ratio, FiO2 requirement) within 24 hours of ICU admission were documented. In addition, early use of corticosteroids and pharmacological venous thromboembolism (VTE) prophylaxis were recorded for the eligible patients Study Outcomes The study aims to assess the efficacy and the safety of TCZ in critically ill older adult patients (aged ≥ 65 years old) with COVID-19. The primary outcome was the in-hospital mortality compared between patients who received TCZ versus the control group during the ICU stay. The secondary outcomes were the 30-day mortality, hospital LOS, ICU LOS, ventilatorfree days (VFDs), and ICU-related complication(s) during the ICU stay (i.e., acute kidney injury, acute liver injury, secondary fungal infection, respiratory failure requiring MV, and the use of inotropes/vasopressors as supportive measures). The primary outcome was in-hospital mortality which was defined as death occurring for any cause during hospital stay; patients who were discharged from the hospital alive were presumed to survive. The remaining secondary outcomes definitions are provided in the Additional file (Table S1 ) We presented numerical variables (continuous variables) as mean and standard deviation (SD), or median and lower quartile (Q1) and upper quartile (Q3), as appropriate and categorical variables as number (percentage). The normality assumptions were assessed for all numerical variables using the Shapiro-Wilk test and graphical representations using histograms and Q-Q plots. Model fit was assessed using the Hosmer-Lemeshow goodness-of-fit test. Baseline characteristics and outcome variables were compared between the two study groups for statistical differences. For categorical variables, we used the Chi-square or Fisher's exact test. We compared the normally distributed continuous variables using student t-test and other non-normally distributed continuous variables with the Mann-Whitney U test. Multivariable Cox proportional hazards regression analyses were performed for the 30-day and in-hospital mortality. Multivariable regression analysis and negative binomial regression were used for the other outcomes considered in this study. The odds ratios (OR), hazard ratio (HR), or estimates with the 95% confidence intervals (CI) were reported as appropriate. Regression analysis was done by considering PS score as one of the covariates in the model. No imputation was made for missing data as the cohort of patients in our study was not derived from random selection. We considered a P value of < 0.05 statistically significant and used SAS version 9.4 for all statistical analyses. Propensity score matching procedure (Proc PS match) (SAS, Cary, NC) was used to match patients who received TCZ (active group) to patients who did not (control group) based on patient's age, APACHE II score, use of systemic corticosteroids, and AKI status within 24 hours of ICU admission. A greedy nearest neighbor matching method was used in which one patient who received TCZ matched with one patient who did not, which eventually produced the smallest within-pair difference among all available pairs with treated patients. Patients were matched only if the difference in the logits of the propensity scores for pairs of patients from the two groups was less than or equal to 0.5 times the pooled estimate of the standard deviation. A total of 1094 patients admitted to the ICU were screened; 368 older adult patients (aged ≥ 65 years old) were eligible based on the selected criteria in Figure 1 . Of those, 51 patients (13.8%) received TCZ during their ICU stay. After propensity score (PS) matching (1:1 ratio), 94 patients were included based on predefined criteria. All included patients received TCZ within 24 hours of ICU admission. Twenty-four patients (47%) received a single dose of TCZ. Before PS matching, the majority of patients were male (65.8 %), with a mean age of 75.6 (SD 7.88). The commonest underlying comorbidities in our patients were hypertension (70.7 %), diabetes mellitus (68.2 %), and dyslipidemia (26.5 %) (Table 1 .) There were some notable differences in the baseline characteristics between the two groups before PS matching. Patients who received TCZ were younger, received more systemic corticosteroids within 24 hours of ICU admission, had higher C-reactive protein (CRP) and ferritin levels at baseline. After adjusting PS matching based on the selected criteria, all baseline, and demographic characteristics were similar between the two groups except for diabetes mellitus which was more prevalent in the control group, as presented in Table 1 . In a crude analysis, there was a significant difference in the in-hospital ( Table 2 . In a Kaplan-Meier curve, the administration of tocilizumab was associated with better survival outcomes in elderly COVID-19 patients as shown in Figure. 2. The mean VFD was longer in crude analysis toward patients who received TCZ with a mean difference of 12.3 (±13.3) days compared to 8.8 (±12.5) days in the control group. However, it failed to reach the statistically significant difference after regression analysis with a beta coefficient (95%CI): 32 (-0.70, 1.34), p-value=0.54. (Table 2) . The ICU and LOS were not statistically significant in patients who received TCZ This multicenter retrospective study found that the in-hospital mortality rate was significantly lower in older adult patients who received TCZ than those who did not. However, the 30-day mortality was numerically lower in the TCZ group but did not reach a statistically significant difference. On the other hand, the in-hospital mortality was statistically significantly lower in elderly patients who received TCZ, which might be due to a longer follow-up period that may In regard to the ICU complications, there were no significant differences in the two study groups. TCZ is a potent immunomodulator that works through competitive inhibition of IL-6 binding to concern with administering such therapy among patients with COVID-19 patients is the serious secondary infections. Several studies have reported more serious secondary infections following TCZ administration [8, 10, 12, 15] . (Alkofide et al., 2021; Bhatraju et al., 2020; Kimmig et al., 2020; Stone et al., 2020) In contrast to these studies, we found a non-significant difference in the rate of secondary fungal infections. Several studies reported similar findings regarding secondary infections with TCZ vs. standard of care. (Aldhaeefi et al., 2021; Kyriakopoulos et al., 2021; Sciascia et al., 2020; Soin et al., 2021 ; Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial., 2021) As far as we know, this is one of the first multicenter studies that investigated the efficacy and safety of TCZ in critically ill older adult patients with COVID-19. In addition, propensity score matching was used to eliminate a greater portion of bias and create a balanced dataset. However, the study is not free of limitations. First, it was a retrospective study that included a relatively small sample size. Second, short follow-up duration may limit capturing further secondary infections or long-term complications. Lastly, our study might be underpowered to detect a difference in long term outcomes This study shows that TCZ administration among critically ill older adults with COVID- The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The study was approved by King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia (Ref.#. NRC21R.434.10). Throughout the study, participants' confidentiality was rigorously preserved by utilizing an anonymous unique serial number for each individual and confining data to just the investigators. Informed consent was not required due to the research method, which was following the policies of the governmental and local research institutes. Not applicable. No author has a conflict of interest in this study. Additional file 1: Table S1 Secondary outcomes definitions ^^ Chi-square test is used to calculate the P-value. ^ Wilcoxon rank sum test is used to calculate the P-value. $ Cox proportional hazards regression analysis is used to calculate hazard ratio (HR) and p-value. $* Generalized linear model is used to calculate beta coefficient (estimates) and p-value. *^Multivariate logistic regression analysis is used to calculate Odds ratio and p-value. Comorbidities and Age Are Associated With Persistent COVID-19 PCR Positivity Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital Receptor Antagonists in Critically Ill Patients with Covid-19 Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy Saudi MoH Protocol for Patients with Suspected of Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection (version 3.1) Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial Clinical features of patients infected with 2019 novel coronavirus in Wuhan IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital WHO Coronavirus Disease (COVID-19) Dashboard Cytokine release syndrome in COVID-19: a major 3 mechanism of morbidity and mortality New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia Pilot prospective open, singlearm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 15 drugs being tested to treat COVID-19 and how they would work Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 We would like to acknowledge all the investigators in the Saudi critical care pharmacy research (SCAPE) platform who participated in this project.